| dc.contributor.author |
de Silva, H.J. |
en_US |
| dc.contributor.author |
Dassanayake, A.S. |
en_US |
| dc.contributor.author |
Manamperi, A. |
en_US |
| dc.contributor.author |
de Silva, A.P. |
en_US |
| dc.date.accessioned |
2014-10-29T09:24:11Z |
|
| dc.date.available |
2014-10-29T09:24:11Z |
|
| dc.date.issued |
2006 |
en_US |
| dc.identifier.citation |
Transplantation Proceedings. 2006; 38(9): 3118-120 |
en_US |
| dc.identifier.issn |
0041-1345 (Print) |
en_US |
| dc.identifier.issn |
1873-2623 (Electronic) |
en_US |
| dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/1711 |
|
| dc.description |
Indexed in MEDLINE |
|
| dc.description.abstract |
We report the treatment outcome in six post-renal transplant patients with lamivudine-resistant hepatitis B virus (LR-HBV) infection using adefovir dipivoxil and followed for 6 to 18 months. Posttransplant immunosuppressive therapy was not altered. Adefovir dipivoxil effectively suppressed hepatitis B virus DNA and improved alanine transferase, although DNA suppression seemed dependent on continued therapy. Nephrotoxicity led to withdrawal of the drug in three patients. This may limit therapeutic usefulness in a significant proportion of post-renal transplant patients with LR-HBV infection. |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.title |
Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with Adefovir dipivoxil: preliminary results |
en_US |
| dc.type |
Article |
en_US |
| dc.identifier.department |
Medicine |
en_US |
| dc.identifier.department |
Pharmacology |
en_US |
| dc.identifier.department |
MMU |
en_US |
| dc.creator.corporateauthor |
Transplantation Society |
en_US |